Lupus (SLE) trials in Spain

In Spain 43 Also abroad 354

43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Badalona, Barcelona, Elche, La Laguna, Madrid, Pamplona, San Sebastián de los Reyes, Santander, Santiago de Compostela, Valencia, Valladolid, Vigo, Vitoria
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Barcelona, Pamplona, Vigo
Age
18 years to 100 years
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Pamplona, Sevilla, Vitoria
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Málaga, Pamplona, Santiago de Compostela, Valencia
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Castello De La Plana, Córdoba, Madrid, Mérida, Valladolid
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Esplugues de Llobregat, Madrid, Valencia
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Sevilla, Valladolid, Zaragoza
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
A Coruña, Badajoz, Barcelona, Castello De La Plana, Las Palmas De Gran Canaria, Madrid, Málaga, Mérida, Sabadell, Santander, Santiago de Compostela, Sevilla, Vigo, Vitoria
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Barcelona, Mérida
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 1Taking people
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Where
Madrid, Pamplona, Santiago de Compostela
Age
18 years to 75 years
People
21 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00
Phase 2Not yet taking people in Spain
A Trial of LAD603 in Patients with Systemic Lupus Erythematosus
Where
Barcelona, Pamplona
Age
18 years and over
People
20 worldwide
Run by
Almirall S.A.
See details and how to join2026-527200-24-00 · EU 2026-527200-24-00
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
Barcelona, Córdoba, Madrid
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Badalona, Barcelona, Galdakao, Madrid, Vitoria
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
A Coruña, Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Valladolid, Vigo
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1Taking people
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Where
Madrid, Málaga, Pamplona, Sevilla
Age
18 years to 60 years
People
90 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00
Phase 3Not yet taking people in Spain
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
A Coruña, Barcelona, Castello De La Plana, Granada, Las Palmas De Gran Canaria, Madrid, Valencia, Vigo. Pontevedra
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Where
Sevilla
Age
18 years to 70 years
People
24 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00
Phase 1Taking people
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Where
Córdoba, Pamplona, Seville, Valencia
Age
18 years to 70 years
People
80 worldwide
Run by
CRISPR Therapeutics
See details and how to joinNCT06925542
Phase 1/2Taking people
A Study of RO7871996 in Participants with Systemic Lupus Erythematosus
Where
Barcelona, Madrid, Pamplona, Sabadell
Age
18 years and over
People
7
Run by
F. Hoffmann-La Roche AG
See details and how to join2026-527221-35-00 · EU 2026-527221-35-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Mérida, Sevilla, Valladolid
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
A Coruña, Badajoz, Barcelona, Castello De La Plana, Madrid, Málaga, Mérida, Murcia, Sabadell, San Cristobal De La Laguna, Santander, Santiago de Compostela, Sevilla, Vigo, Vitoria
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1/2Taking people
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Where
Madrid, Pamplona
Age
12 years to 65 years
People
28 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01
Phase 1Not yet taking people in Spain
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
Where
Barcelona, Vitoria
Age
Up to 64 years
People
10 worldwide
Run by
UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Barcelona, Castello De La Plana, Santander, Sevilla
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Barcelona, Madrid, Santander
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798